A pharma exec raised the price of antibiotic by 400 percent — and the government can’t do much about
From the article:
Three years after Martin Shkreli became the poster boy of pharmaceutical company greed, another drug company executive is setting himself up for a similar infamy. And now, just as then, there is little the government can do — besides make a fuss.
Nirmal Mulye, CEO of Nostrum Laboratories, quadrupled the price of a generic liquid antibiotic used to treat bladder infections, the Financial Times reportedTuesday. And he had little shame.
“I think it is a moral requirement to make money when you can … to sell the product for the highest price,” Mulye told the FT.health law policy pharmaceuticals